Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Baxter
Johnson and Johnson
McKinsey
Merck
Harvard Business School
Mallinckrodt

Last Updated: October 18, 2019

DrugPatentWatch Database Preview

Claims for Patent: 9,144,585

See Plans and Pricing

« Back to Dashboard

Summary for Patent: 9,144,585
Title:Isolated mesenchymal progenitor cells and extracellular matrix produced thereby
Abstract: Provided are methods of isolating an extracellular matrix from mesenchymal progenitor cells which are characterized by a reduced differentiation ability into an adipogenic lineage as compared to adipose-derived mesenchymal stem cells. Also provide isolated extracellular matrix and hybrid devices comprising electrospun elements and extracellular matrix which can be used for various tissue regeneration, repair and reconstruction surgeries.
Inventor(s): Itskovitz-Eldor; Joseph (Haifa, IL), Shtrichman; Ronit (Haifa, IL), Zussman; Eyal (Haifa, IL), Barak; Efrat (Nofit, IL)
Assignee: Technion Research & Development Foundation Limited (Haifa, IL)
Application Number:13/812,552
Patent Claims:1. A method of isolating an extracellular matrix, comprising: (a) obtaining induced pluripotent stem cells (iPSCs) derived from plucked human hair follicle keratinocytes (HFKTs); (b) generating embryoid bodies (EBs) from said iPSCs; (c) generating single cells from adherent cells of said EBs, and (d) culturing said single cells in a culture medium which comprises ascorbic acid and does not comprise dexamethasone to thereby obtain a population of mesenchymal progenitor cells which comprises at least 70% CD105+ cells, wherein said mesenchymal progenitor cells exhibit at least 70% reduced differentiation potential into an adipogenic lineage as compared to differentiation of mesenchymal stem cells from an adult adipose source under identical assay conditions as analyzed after 28-30 days of culturing in a medium which comprises 10.sup.-6 M dexamethasone and indomethacin; and subsequently, (e) culturing said mesenchymal progenitor cells produced in step (d) under conditions which induce production of extracellular matrix from said mesenchymal progenitor cells, and subsequently, (f) isolating the extracellular matrix produced by said mesenchymal progenitor cells, thereby isolating the extracellular matrix.

2. The method of claim 1, further comprising decellularizing said extracellular matrix.

3. The method of claim 1, wherein said single cells from adherent cells of said EBs are obtained by: (a) dissociating the EBs to cell aggregates, (b) culturing said cell aggregates on a low-adhesive surface so as to select a population of adherent cells, and (c) dissociating said adherent cells to single cells.

4. The method of claim 1, wherein said EBs are 8-14 day-old human EBs.

5. The method of claim 3, wherein each of said aggregates comprises about 10-30 cells.

6. The method of claim 3, wherein said dissociating said EBs into said aggregates is effected using Collagenase B.

7. The method of claim 3, wherein said adherent cells are expanded by at least 2 fold within 2-3 days of culturing in said culture medium.

8. The method of claim 1, wherein differentiation into an osteogenic lineage of said mesenchymal progenitor cells is increased by at least 50% as compared to differentiation of mesenchymal stem cells from an adult adipose source under identical assay conditions.

9. The method of claim 1, wherein said culturing in step (e) is performed on an electrospun element.

10. The method of claim 1, wherein at least 70% of said population of mesenchymal progenitor cells are CD105+/CD90+.

11. The method of claim 1, wherein at least 70% of said population of mesenchymal progenitor cells are characterized by a CD105+/CD90+/CD73+/CD44+/CD29+ signature.

12. The method of claim 1, wherein at least 70% of said population of mesenchymal progenitor cells are characterized by a CD105+/CD45-/CD34- signature.

13. The method of claim 1, wherein said mesenchymal progenitor cells maintain the ability to form extracellular matrix for at least 8 passages.

14. The method of claim 1, wherein said culturing in step (d) is performed for 1-15 passages.

15. The method of claim 1, wherein said iPSCs are lentiviral vector-free iPSCs.

Summary for Patent:   Start Trial

PCT Information
PCT FiledJuly 27, 2011PCT Application Number:PCT/IL2011/000604
PCT Publication Date:February 02, 2012PCT Publication Number:WO2012/014205

Details for Patent 9,144,585

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Advance Biofactures SANTYL collagenase VIAL 101995 001 1965-06-04   Start Trial Technion Research & Development Foundation Limited (Haifa, IL) 2030-07-27 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

International Patent Family for US Patent 9,144,585

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Johnson and Johnson
Medtronic
Colorcon
McKinsey
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.